Literature DB >> 24696055

Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.

Sophie Thoo1, Sudha Cugati1, Andrew Lee2, Celia Chen3.   

Abstract

The occurrence of macular edema as an adverse effect of fingolimod is well documented. Treatment modalities used to manage fingolimod-associated macular edema (FAME) have included nonsteroidal anti-inflammatory agents and sub-tenon injection. We describe two cases where intravitreal injection is used to successfully treat FAME in patients who were previously unsuccessfully treated with topical nonsteroidal anti-inflammatories.
© The Author(s), 2015.

Entities:  

Keywords:  Fingolimod; edema; multiple sclerosis; steroid

Mesh：

Substances：

Year:  2014        PMID： 24696055     DOI： 10.1177/1352458514528759

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Fingolimod-associated severe bilateral cystoid macular edema.

Authors:  Hideki Fukuoka; Kentaro Kojima; Ayako Iwama; Takahiro Okumura; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-22

Review 3.  Fingolimod: therapeutic mechanisms and ocular adverse effects.

Authors:  P Mandal; A Gupta; W Fusi-Rubiano; P A Keane; Y Yang
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

4.  Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?

Authors:  Refik Pul; Alma Osmanovic; Holger Schmalstieg; Amelie Pielen; Kaweh Pars; Philipp Schwenkenbecher; Kurt Wolfram Sühs; Özlem Yildiz; Benedikt Frank; Martin Stangel; Thomas Skripuletz
Journal:  Int J Mol Sci       Date:  2016-12-14       Impact factor: 5.923

Review 5.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28

6.  Diagnosis and Management of Fingolimod-Associated Macular Edema.

Authors:  Chunjiang Wang; Zhenzhen Deng; Liying Song; Wei Sun; Shaoli Zhao
Journal:  Front Neurol       Date:  2022-07-15       Impact factor: 4.086

7.  Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.

Authors:  Hisanao Akiyama; Yu Suzuki; Daisuke Hara; Kensuke Shinohara; Hana Ogura; Masashi Akamatsu; Yasuhiro Hasegawa
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 8.  Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.

Authors:  Heather E Moss
Journal:  Eye Brain       Date:  2017-06-29

9.  Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications.

Authors:  Rachel Husmann; John B Davies; Malik Ghannam; Brent Berry; Praful Kelkar
Journal:  Clin Mol Allergy       Date:  2020-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.